Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia

Dingwei Ye, Masatoshi Eto, Jin Soo Chung, Go Kimura, Wen Cheng Chang, Yen Hwa Chang, See Tong Pang, Jae Lyun Lee, Yuanjie Niu, Howard Gurney, Hirotsugu Uemura

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

    LanguageEnglish
    Pages225-233
    Number of pages9
    JournalClinical Genitourinary Cancer
    Volume12
    Issue number4
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Korea
    Taiwan
    Renal Cell Carcinoma
    China
    Japan
    Therapeutics
    Physicians
    Republic of Korea
    Geography
    Incidence
    Proxy
    Cell- and Tissue-Based Therapy
    Ethnic Groups
    Clinical Trials
    Guidelines
    Morbidity
    Mortality
    Pharmaceutical Preparations

    Cite this

    Ye, Dingwei ; Eto, Masatoshi ; Chung, Jin Soo ; Kimura, Go ; Chang, Wen Cheng ; Chang, Yen Hwa ; Pang, See Tong ; Lee, Jae Lyun ; Niu, Yuanjie ; Gurney, Howard ; Uemura, Hirotsugu. / Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region : opinion statement from China, Japan, Taiwan, Korea, and Australia. In: Clinical Genitourinary Cancer. 2014 ; Vol. 12, No. 4. pp. 225-233.
    @article{13c45677c52f4a128de384549211dbfd,
    title = "Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia",
    abstract = "Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.",
    author = "Dingwei Ye and Masatoshi Eto and Chung, {Jin Soo} and Go Kimura and Chang, {Wen Cheng} and Chang, {Yen Hwa} and Pang, {See Tong} and Lee, {Jae Lyun} and Yuanjie Niu and Howard Gurney and Hirotsugu Uemura",
    year = "2014",
    doi = "10.1016/j.clgc.2014.01.007",
    language = "English",
    volume = "12",
    pages = "225--233",
    journal = "Clinical Genitourinary Cancer",
    issn = "1558-7673",
    publisher = "Elsevier",
    number = "4",

    }

    Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region : opinion statement from China, Japan, Taiwan, Korea, and Australia. / Ye, Dingwei; Eto, Masatoshi; Chung, Jin Soo; Kimura, Go; Chang, Wen Cheng; Chang, Yen Hwa; Pang, See Tong; Lee, Jae Lyun; Niu, Yuanjie; Gurney, Howard; Uemura, Hirotsugu.

    In: Clinical Genitourinary Cancer, Vol. 12, No. 4, 2014, p. 225-233.

    Research output: Contribution to journalReview articleResearchpeer-review

    TY - JOUR

    T1 - Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region

    T2 - Clinical Genitourinary Cancer

    AU - Ye, Dingwei

    AU - Eto, Masatoshi

    AU - Chung, Jin Soo

    AU - Kimura, Go

    AU - Chang, Wen Cheng

    AU - Chang, Yen Hwa

    AU - Pang, See Tong

    AU - Lee, Jae Lyun

    AU - Niu, Yuanjie

    AU - Gurney, Howard

    AU - Uemura, Hirotsugu

    PY - 2014

    Y1 - 2014

    N2 - Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

    AB - Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

    UR - http://www.scopus.com/inward/record.url?scp=84904766934&partnerID=8YFLogxK

    U2 - 10.1016/j.clgc.2014.01.007

    DO - 10.1016/j.clgc.2014.01.007

    M3 - Review article

    VL - 12

    SP - 225

    EP - 233

    JO - Clinical Genitourinary Cancer

    JF - Clinical Genitourinary Cancer

    SN - 1558-7673

    IS - 4

    ER -